Transcat’s (TRNS) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Transcat (NASDAQ:TRNS) in a research note published on Wednesday morning, Benzinga reports. They currently have a $130.00 target price on the scientific and technical instruments company’s stock, down from their previous target price of $155.00.

A number of other brokerages also recently commented on TRNS. StockNews.com downgraded Transcat from a “hold” rating to a “sell” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $156.00 price target on shares of Transcat in a research note on Tuesday. Finally, Craig Hallum dropped their price objective on shares of Transcat from $138.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $127.25.

Transcat Price Performance

Shares of Transcat stock opened at $95.41 on Wednesday. The stock has a market capitalization of $873.00 million, a price-to-earnings ratio of 48.19 and a beta of 0.67. The business has a 50-day moving average of $121.71 and a 200 day moving average of $121.89. Transcat has a 12 month low of $84.45 and a 12 month high of $147.12.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings data on Monday, October 28th. The scientific and technical instruments company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.12). The business had revenue of $67.83 million during the quarter, compared to analyst estimates of $70.30 million. Transcat had a net margin of 6.63% and a return on equity of 7.62%. The company’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.41 EPS. Equities research analysts anticipate that Transcat will post 2.06 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale purchased a new stake in Transcat during the second quarter worth about $40,000. nVerses Capital LLC purchased a new position in Transcat during the third quarter worth $60,000. First Horizon Advisors Inc. raised its stake in Transcat by 26.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the scientific and technical instruments company’s stock valued at $72,000 after purchasing an additional 125 shares during the last quarter. Fifth Third Bancorp raised its position in shares of Transcat by 95.8% in the second quarter. Fifth Third Bancorp now owns 656 shares of the scientific and technical instruments company’s stock valued at $79,000 after buying an additional 321 shares during the last quarter. Finally, Quest Partners LLC acquired a new position in Transcat in the 2nd quarter valued at $109,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.